SCHEMBL6996033

SCHEMBL6996033

C1CC2CC3CC1CC(C2)C3

nearest known ligand 0.38

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23926890 0.94
SCHEMBL136714 0.94
Adamantane SCHEMBL2394879 0.89 CYP2C9 (0.38) CYP2C9
SCHEMBL1230616 0.82 SLC22A2 (0.31) CYP2C9
SCHEMBL8189 0.82
SCHEMBL3226595 0.82 SLC22A2 (0.31) CYP2C9
Adamantane SCHEMBL9016497 0.82 CYP2C9 (0.46) CYP2C9
Adamantane SCHEMBL29707714 0.82 CYP2C9 (0.46) CYP2C9
Adamantane SCHEMBL12761 0.82 CYP2C9 (0.46) CYP2C9
Adamantane SCHEMBL1527414 0.82 CYP2C9 (0.46) CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4053223-B1 COMPOSITIONS FOR USE IN OPTICAL MEASUREMENT TECHNOLOGY APPLICATIONS F2MB ENG UG HAFTUNGSBESCHRAENKT (DE) 2025-05-14 EP claimed
US-20240174871-A1 Compositions for Use in Optical Measurement Technology Applications F2MB-ENGINEERING UG (DE) 2024-05-30 US claimed
CN-117440992-A Use of a composition in optical measurement applications F2MB-工程公司 2024-01-23 CN claimed
WO-2022184834-A1 COMPOSITIONS FOR USE IN OPTICAL MEASUREMENT TECHNOLOGY APPLICATIONS F2MB-ENGINEERING UG (DE) 2022-09-09 WO claimed
EP-4053223-A1 COMPOSITIONS FOR USE IN OPTICAL MEASUREMENT TECHNOLOGY APPLICATIONS F2MB-Engineering UG (haftungsbeschränkt) (DE) 2022-09-07 EP claimed
EP-4728019-A1 A MICROWAVE CARBONIZATION ASSEMBLY AND METHOD FOR EXTRACTING COMPONENTS FROM RUBBER Sable Rubber IP Pty Limited (AU) 2026-04-22 EP disclosed
US-20250185505-A1 NITROGENOUS HETEROCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES UDC IRELAND LIMITED (IE) 2025-06-05 US disclosed
US-20250171684-A1 AROMATIC HETREOCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES UDC IRELAND LIMITED (IE) 2025-05-29 US disclosed
EP-4053223-B1 COMPOSITIONS FOR USE IN OPTICAL MEASUREMENT TECHNOLOGY APPLICATIONS F2MB ENG UG HAFTUNGSBESCHRAENKT (DE) 2025-05-14 EP disclosed
CN-119498028-A Carbon mold for DRAM capacitor 应用材料公司 2025-02-21 CN disclosed
CN-119241343-A Highly adamantane type phloroglucinol compound and preparation method and application thereof 中日友好医院(中日友好临床医学研究所) 2025-01-03 CN disclosed
WO-2024257019-A1 A MICROWAVE CARBONIZATION ASSEMBLY AND METHOD FOR EXTRACTING COMPONENTS FROM RUBBER Molectra Rubber IP Pty Ltd (AU) 2024-12-19 WO disclosed
US-20020028808-A1 Use of potassium channel agonists for the treatment of cancer NOVO NORDISK A/S (DK) 2002-03-07 US disclosed
WO-2002000222-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER NOVO NORDISK A/S (DK) 2002-01-03 WO disclosed
WO-2002000223-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION NOVO NORDISK A/S (DK) 2002-01-03 WO disclosed
US-6329367-B1 NERVOUS SYSTEM DISORDERS AND CARDIOVASCULAR DISORDERS NOVO NORDISK A/S (DK) 2001-12-11 US disclosed
EP-1140945-A1 FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-10-10 EP disclosed
WO-2000076505-A1 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-12-21 WO disclosed
WO-2000037474-A1 FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-06-29 WO disclosed
WO-1995028155-A1 PHOSPHONATE DERIVATIVES OF LIPOPHILIC AMINES RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1995-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171684-A1 AROMATIC HETREOCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES AHR, PAH, DDT CYP2C9 39/4885
US-20250185505-A1 NITROGENOUS HETEROCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES NES, NUDC, HCN2 CYP2C9 857/4885
US-20020028808-A1 Use of potassium channel agonists for the treatment of cancer KCNN3, KCNN1, KCNN2 CYP2C9 3315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.